UA/NSTEMI: Are you following the latest guidelines?

Nursing

Volumn 42, Issue 9, 2012, Pages 26-33

  Dechant, Laura M ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; PIPERAZINE DERIVATIVE; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICAGRELOR;

CHRONIC KIDNEY FAILURE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; NURSING; PATIENT EDUCATION; PRACTICE GUIDELINE; REVIEW; UNSTABLE ANGINA PECTORIS;

ADENOSINE; ANGINA, UNSTABLE; ANTICOAGULANTS; BLOOD GLUCOSE; GUIDELINE ADHERENCE; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL INFARCTION; PATIENT EDUCATION AS TOPIC; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 84865773710     PISSN: 03604039     EISSN: 15388689     Source Type: Journal    
DOI: 10.1097/01.NURSE.0000418611.61100.ca     Document Type: Article

References (14)

1. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable angina/non-ST- elevation Myocardial Infarction (updating the 2007 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):2022-2060.
2. Effient (prasugrel) tablets. Highlights of prescribing information. http://pi.lilly.com/us/effient.pdf.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20):2001-2015.
4. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718.
5. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937-944.
6. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: The NHLBI dynamic registry. J Am Coll Cardiol. 2009; 53(suppl A):A27-A28.
7. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4): 363-375.
8. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2010; 56(24):2051-2066.
9. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF; VALOR investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: The Visipaque angiography/interventions with laboratory outcomes in renal insufficiency (VALOR) trial. Am Heart J. 156(4): 776-782.
10. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283- 1297.
11. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport trials. J Interv Cardiol. 2003;16(4):299-305.
12. Porth CM. Essentials of Pathophysiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
13. Brilinta (ticagrelor). Highlights of prescribing information. http://www1.astrazeneca-us.com/pi/brilinta.pdf.
14. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057